CONMED Valuation
| CNMD Stock | USD 41.80 0.13 0.31% |
At this time, the firm appears to be undervalued. CONMED shows a prevailing Real Value of $44.37 per share. The current price of the firm is $41.8. Our model approximates the value of CONMED from reviewing the firm fundamentals such as return on equity of 0.0478, and Profit Margin of 0.03 % as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting CONMED's valuation include:
Price Book 1.2799 | Enterprise Value | Enterprise Value Ebitda 20.5986 | Price Sales 0.9416 | Forward PE 27.027 |
Undervalued
Today
Please note that CONMED's price fluctuation is very steady at this time. Calculation of the real value of CONMED is based on 3 months time horizon. Increasing CONMED's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the CONMED stock is determined by what a typical buyer is willing to pay for full or partial control of CONMED. Since CONMED is currently traded on the exchange, buyers and sellers on that exchange determine the market value of CONMED Stock. However, CONMED's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 41.8 | Real 44.37 | Target 47.4 | Hype 41.74 |
The real value of CONMED Stock, also known as its intrinsic value, is the underlying worth of CONMED Company, which is reflected in its stock price. It is based on CONMED's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of CONMED's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of CONMED helps investors to forecast how CONMED stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of CONMED more accurately as focusing exclusively on CONMED's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use CONMED's intrinsic value based on its ongoing forecasts of CONMED's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against CONMED's closest peers. If more than one evaluation category is relevant for CONMED we suggest using both methods to arrive at a better estimate.
CONMED Cash |
|
CONMED Revenue by Product
CONMED Total Value Analysis
CONMED is currently expected to have valuation of 2.11 B with market capitalization of 1.29 B, debt of 905.78 M, and cash on hands of 33.35 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the CONMED fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.11 B | 1.29 B | 905.78 M | 33.35 M |
CONMED Investor Information
About 99.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.28. Some equities with similar Price to Book (P/B) outperform the market in the long run. CONMED has Price/Earnings (P/E) ratio of 188.03. The entity last dividend was issued on the 15th of September 2025. The firm had 3:2 split on the 10th of September 2001. Based on the measurements of operating efficiency obtained from CONMED's historical financial statements, CONMED is performing exceptionally good at this time. It has a great probability to report excellent financial results in March.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Operating Profit Margin | 0.12 | 0.0947 |
|
| |||||
| Total Cash From Operating Activities | 201.6 M | 192 M |
|
| |||||
| Operating Income | 136.6 M | 130.1 M |
|
|
CONMED Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. CONMED has an asset utilization ratio of 59.61 percent. This indicates that the Company is making $0.6 for each dollar of assets. An increasing asset utilization means that CONMED is more efficient with each dollar of assets it utilizes for everyday operations.CONMED Profitability Analysis
Based on the measurements of profitability obtained from CONMED's financial statements, CONMED is yielding more profit at this time then in previous quarter. It has a moderate probability of reporting better profitability numbers in March. Profitability indicators assess CONMED's ability to earn profits and add value for shareholders.Net Income | First Reported 1986-03-31 | Previous Quarter 2.9 M | Current Value 16.7 M | Quarterly Volatility 16.9 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.42 | 0.5387 |
|
| |||||
| Operating Profit Margin | 0.12 | 0.0947 |
|
|
For CONMED profitability analysis, we use financial ratios and fundamental drivers that measure the ability of CONMED to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well CONMED utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between CONMED's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of CONMED over time as well as its relative position and ranking within its peers.
CONMED Earnings per Share Projection vs Actual
The next projected EPS of CONMED is estimated to be 0.8184 with future projections ranging from a low of 0.81 to a high of 0.8306. CONMED's most recent 12-month trailing earnings per share (EPS TTM) is at 1.51. Please be aware that the consensus of earnings estimates for CONMED is based on EPS before non-recurring items and includes expenses related to employee stock options.CONMED Earnings Estimation Breakdown
The calculation of CONMED's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of CONMED is estimated to be 0.8184 with the future projection ranging from a low of 0.81 to a high of 0.8306. Please be aware that this consensus of annual earnings estimates for CONMED is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.81 Lowest | Expected EPS | 0.83 Highest |
CONMED Earnings Projection Consensus
Suppose the current estimates of CONMED's value are higher than the current market price of the CONMED stock. In this case, investors may conclude that CONMED is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and CONMED's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2026 | Current EPS (TTM) | |
| 6 | 84.3% | 1.43 | 0.8184 | 1.51 |
CONMED Ownership Allocation
The majority of CONMED outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in CONMED to benefit from reduced commissions. Thus, institutional investors are subject to a different set of regulations than regular investors in CONMED. Please pay attention to any change in the institutional holdings of CONMED as this could imply that something significant has changed or is about to change at the company.CONMED Profitability Analysis
The company reported the previous year's revenue of 1.37 B. Net Income was 132.42 M with profit before overhead, payroll, taxes, and interest of 785.17 M.CONMED Past Distributions to stockholders
| 3rd of October 2025 | ||
| 3rd of July 2025 | ||
| 4th of April 2025 | ||
| 3rd of January 2025 | ||
| 4th of October 2024 | ||
| 5th of July 2024 | ||
| 5th of April 2024 |
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates CONMED's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in CONMED and how it compares across the competition.
About CONMED Valuation
The stock valuation mechanism determines CONMED's current worth on a weekly basis. Our valuation model uses a comparative analysis of CONMED. We calculate exposure to CONMED's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of CONMED's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 740.6 M | 777.6 M | |
| Pretax Profit Margin | 0.05 | 0.08 | |
| Operating Profit Margin | 0.09 | 0.12 | |
| Net Profit Margin | 0.03 | 0.05 | |
| Gross Profit Margin | 0.54 | 0.42 |
CONMED Quarterly Retained Earnings |
|
A single share of CONMED represents a small ownership stake in the entity. As a stockholder of CONMED, your percentage of company ownership is determined by dividing the number of shares you own by the total number of shares outstanding and then multiplying that amount by 100. Owning stock in a company generally confers both corporate voting rights and income from any dividends paid to the stock owner.
CONMED Dividends Analysis For Valuation
The current year's Dividend Payout Ratio is expected to grow to 0.69, whereas Dividends Paid is projected to grow to (21.1 M). . At present, CONMED's Price Earnings Ratio is projected to decrease significantly based on the last few years of reporting.
| Last Reported | Projected for Next Year | ||
| Dividends Paid | -22.2 M | -21.1 M | |
| Dividend Yield | 0.01 | 0.01 | |
| Dividend Payout Ratio | 0.40 | 0.69 | |
| Dividend Paid And Capex Coverage Ratio | 5.09 | 2.90 |
There are various types of dividends CONMED can pay to its shareholders, and the actual value of the dividend is determined on a per-share basis. It is to be paid equally to all of CONMED shareholders on a specific date, known as the payable date. The cash dividend is the most common type of dividend payment - it is the payment of actual cash from CONMED directly to its shareholders. There are other types of dividends that companies can issue, such as stock dividends or asset dividends. When CONMED pays a dividend, it has no impact on its enterprise value. It does, however, lowers the Equity Value of CONMED by the value of the dividends paid out.
CONMED Growth Indicators
Investing in growth stocks can be very risky. If the company such as CONMED does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 31.1 M | |
| Quarterly Earnings Growth Y O Y | -0.5 | |
| Forward Price Earnings | 27.027 |
CONMED Current Valuation Indicators
Valuation refers to the process of determining the present value of CONMED and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value CONMED we look at many different elements of the entity such as CONMED's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as CONMED, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use CONMED's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes CONMED's worth.Complementary Tools for CONMED Stock analysis
When running CONMED's price analysis, check to measure CONMED's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CONMED is operating at the current time. Most of CONMED's value examination focuses on studying past and present price action to predict the probability of CONMED's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CONMED's price. Additionally, you may evaluate how the addition of CONMED to your portfolios can decrease your overall portfolio volatility.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |